UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Historical Holders from Q2 2017 to Q3 2025

Symbol
URGN on Nasdaq
CUSIP
M96088105
Type / Class
Equity / Ordinary Shares, par value NIS 0.01 per share
Shares outstanding
46.2M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
43.9M
Holdings value
$877M
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
157
Number of buys
80
Number of sells
-66
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Paradigm Biocapital Advisors LP 9% +80% $84.1M $37.6M 4.22M +80.8% Paradigm BioCapital Advisors LP Sep 30, 2025
TORONTO DOMINION BANK 6.9% $63.7M 3.19M The Toronto-Dominion Bank Sep 30, 2025
MORGAN STANLEY 5.4% +180% $25.2M $17.6M 2.49M +231% Morgan Stanley Jun 30, 2025
MENORA MIVTACHIM HOLDINGS LTD. 4.99% $22.2M 2.3M Menora Mivtachim Holdings Ltd Mar 11, 2025
BlackRock, Inc. 5% $23.2M 2.28M BlackRock, Inc. Jun 30, 2025
Soleus Capital Master Fund, L.P. 4.7% -6% $22.2M -$1.42M 2.19M -6.02% Soleus Capital Master Fund, L.P. Jun 30, 2025
Adage Capital Management, L.P. 2.77% -59.6% $12.3M -$15.9M 1.28M -56.4% Adage Capital Management, L.P. Mar 31, 2025
Monograph Capital Holdings Advisors, LLC 1.8% $8.5M 839K Monograph Capital Partners I, L.P. Jun 5, 2025

Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 43.9M $877M +$94.3M $19.95 157
2025 Q2 39.8M $545M +$3.48M $13.70 149
2025 Q1 41.6M $461M +$59.8M $11.06 139
2024 Q4 36.3M $386M -$9.61M $10.65 138
2024 Q3 35.1M $446M -$58.5M $12.70 127
2024 Q2 38.2M $641M +$95.8M $16.78 115
2024 Q1 626K $9.38M -$5.64M $15.00 9
2023 Q4 44.4K $666K +$222K $15.00 2
2023 Q3 17.7M $248M +$65.7M $14.01 99
2023 Q2 13.2M $137M +$7.29M $10.35 84
2023 Q1 12.4M $115M -$4.57M $9.24 64
2022 Q4 13M $115M -$2.4M $8.87 63
2022 Q3 13.3M $110M -$658K $8.32 55
2022 Q2 13.1M $107M -$6.23M $8.19 58
2022 Q1 14.2M $124M +$1.4M $8.71 81
2021 Q4 14.5M $138M +$2.03M $9.51 68
2021 Q3 14.1M $237M +$1.89M $16.82 89
2021 Q2 12.1M $184M -$6.03M $15.27 76
2021 Q1 14.3M $278M -$4.16M $19.48 88
2020 Q4 14.5M $261M -$10.5M $18.02 80
2020 Q3 15M $289M +$6.24M $19.29 78
2020 Q2 14.7M $382M +$28.3M $26.12 83
2020 Q1 13.3M $237M -$16.6M $17.84 76
2019 Q4 14.2M $473M +$4.84M $33.37 85
2019 Q3 14.6M $347M -$26.2M $23.83 82
2019 Q2 14.7M $527M +$44.8M $35.94 83
2019 Q1 13.5M $497M +$143M $36.94 73
2018 Q4 9.15M $394M +$17.9M $43.06 62
2018 Q3 9.92M $468M +$14.1M $47.23 69
2018 Q2 9.6M $482M +$24.1M $49.76 60
2018 Q1 9.14M $454M +$119M $49.69 43
2017 Q4 6.84M $254M +$70M $37.21 41
2017 Q3 4.6M $144M +$1.64M $31.52 31
2017 Q2 4.72M $85.2M +$85.2M $18.06 20